PharmaShots | Incisive News in 3 Shots

Subscribe Now

Advances

Lannett to Submit Biosimilar Application to the US FDA for its Insulin Glargine by the End of 2022

Lannett to Submit Biosimilar Application to the US FDA for its Insulin Glargine by the End of 2022

June 12, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us